Bio-Rad Shares Sink 5% After-Hours on Q1 Earnings Miss and Guidance Cut

Guidance Slash Triggers Extended Trading Sell-Off

Bio-Rad Laboratories (BIO) saw its stock price plunge 5.03% in after-hours trading on Thursday, following the release of its first-quarter 2026 financial results. The move was a sharp divergence from the broader market, as the S&P 500 remained virtually flat during the session. The primary catalyst for the sell-off was a significant downward revision to the company's full-year 2026 financial outlook, signaling that the recovery in life science research spending is taking longer than management previously anticipated.

For the full year 2026, Bio-Rad now expects non-GAAP, currency-neutral revenue to range between a decline of 3.0% and growth of just 0.5%. This is a stark reduction from its prior guidance of 0.5% to 1.5% growth. Furthermore, the company trimmed its non-GAAP operating margin estimate to a range of 10.0% to 12.0%, down from the previous target of 12.0% to 12.5%.

Quarterly Performance Misses the Mark

The company reported first-quarter total net sales of $592.1 million, a modest 1.1% increase on a reported basis but a 4.2% decline when measured on a currency-neutral basis. This figure fell short of the $594.8 million consensus estimate. Non-GAAP diluted earnings per share (EPS) came in at $1.89, down from $2.54 in the same period last year, reflecting significant margin compression.

On a GAAP basis, the company recorded a massive net loss of $527.1 million, or $19.55 per share. However, this headline figure was primarily driven by a $738.2 million loss related to the change in fair market value of the company's equity investment in Sartorius AG. While investors often strip out these non-cash investment fluctuations, the underlying operational weakness in the core business was the clear focus of the after-hours session, which saw 643.5K shares change hands.

Segment Weakness and Macro Headwinds

Performance was soft across both of Bio-Rad's primary reporting segments. The Life Science unit saw currency-neutral sales decline 4.3%, pressured by ongoing challenges in the academic research market, particularly in the Americas. Meanwhile, the Clinical Diagnostics segment saw a 4.1% currency-neutral decline, which management attributed to business disruptions stemming from escalating regional conflicts in the Middle East.

CEO Norman Schwartz noted that the results reflected a "dynamic environment" and "external headwinds," though he highlighted the company's ability to generate $78.1 million in free cash flow during the quarter. Despite this cash generation, the market's reaction suggests that the combination of a revenue miss and a lowered growth trajectory has severely dampened sentiment.

Market Context and Analyst Sentiment

Today's plunge follows a period of growing caution among Wall Street analysts. Citigroup recently downgraded Bio-Rad to Neutral, citing concerns over process chromatography margins and the company's exposure to the diagnostics market in China. With the stock now trading sharply lower in the extended session, investors will likely remain focused on whether the company can stabilize its margins in the face of persistent biopharma and academic spending constraints. Looking forward, the market will be watching for any signs of a rebound in instrument sales, which management indicated have been slower to recover than expected.